Clinical Trial

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Name: Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer — clinical trial record (NCT07153965)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, single-arm, multicenter phase II study to evaluate the safety and efficacy of sac-TMT plus Tagitanlimab in patients with PD-L1-positive locally advanced or metastatic TNBC.

Trial Details

NCT Number	NCT07153965
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Triple Negative Breast Cancer (TNBC), PD-L1 Positive
Enrollment	47 participants
Start Date	2025-09-01
Primary Completion	2026-09-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-04